We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Mount Sinai Hospital in New York and Cleveland Clinic are the latest large players in healthcare to flash a red light at Biogen’s controversial new Alzheimer’s drug Aduhelm. Read More
The Jan. 4 proposal by NIST would have weakened one of the few tools the federal government has to directly reduce the price of new prescription drugs. Read More
As state law is pre-empted by federal law, generics makers could not update their labeling or redesign their ranitidine products because the FDA had not approved those changes, the judge said. Read More
AstraZeneca’s acquisition of Boston-based Alexion Pharmaceuticals has been cleared by the UK’s Competition and Markets Authority — passing the final hurdle that will allow the $39 billion deal to close next week. Read More
Drug wholesalers’ claims that Eli Lilly, Sanofi, Novo Nordisk and a group of pharmacy benefit managers (PBMs) engaged in racketeering can proceed, said a federal judge, who at the same time dismissed antitrust allegations that the companies worked together to overcharge for diabetes drugs. Read More
The FDA’s approval of Biogen’s Aduhelm for treatment of Alzheimer’s disease (AD) has taken regulators, payers and patients to an unprecedented intersection of medical need, clinical benefit and cost. Read More
Federal overreach in attempting to curb patent practices that allegedly lead to high drug prices could stifle innovation, an attorney for the Pharmaceutical Research and Manufacturers of America (PhRMA) told a Senate subcommittee yesterday. Read More
The Biden administration has walked back a proposal from the waning days of the Trump administration that would have restricted federal use of march-in rights for drugs. Read More